Norfolk, VA, June 29, 2020 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer, is scheduled to participate in Oppenheimer’s Private Life Sciences Company Call Series on Tuesday, June 30, 2020 at 9:30am ET. Dr. Thienel will discuss the use of ReAlta’s dual targeting peptide technology platform to deliver game-changing new therapies for acute lung injury related to COVID-19 and hypoxic-ischemic encephalopathy (HIE).
ABOUT REALTA — ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs. To support its vision, ReAlta has developed a novel class of therapeutics with a dual targeting approach designed to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071 (PIC1-dPEG24), which has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates. The company launched in 2018 and is located in Norfolk, Virginia.
Norfolk, VA, February 16, 2021 – ReAlta Life Sciences, Inc. (“ReAlta”), a company addressing life-threatening diseases through harnessing the power...Read More
Norfolk, VA, December 3, 2020 — ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted Orphan...Read More
Norfolk, VA, November 19, 2020 — Norfolk, Virginia, known globally for its expertise in resilience and strong entrepreneurship ecosystem, is...Read More